Fixed-dose combination inhaler's commercial revenue optimization — the commercial product architecture of combining inhaled corticosteroid and long-acting beta-agonist drugs in a single inhaler device — eliminating the need for patients to use separate ICS and LABA inhalers — generating both superior clinical adherence outcomes over dual-device regimens and higher...